<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Schizophr Bull</journal-id><journal-id journal-id-type="iso-abbrev">Schizophr Bull</journal-id><journal-id journal-id-type="publisher-id">schbul</journal-id><journal-title-group><journal-title>Schizophrenia Bulletin</journal-title></journal-title-group><issn pub-type="ppub">0586-7614</issn><issn pub-type="epub">1745-1701</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5888558</article-id><article-id pub-id-type="doi">10.1093/schbul/sby014.169</article-id><article-id pub-id-type="publisher-id">sby014.169</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Concurrent Symposia</subject></subj-group></subj-group></article-categories><title-group><article-title>41.1 WHAT DO META-ANALYSES TELL US ABOUT CLOZAPINE&#x02019;S EFFICACY AND EFFECTIVENESS FOR TREATMENT REFRACTORY SCHIZOPHRENIA?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Siskind</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Kisely</surname><given-names>Steve</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Land</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>McCartney</surname><given-names>Lara</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Metro South Addiction and Mental Health Service</aff><aff id="AF0002"><label>2</label>University of Queensland, MSAMHS</aff><aff id="AF0003"><label>3</label>University of Queensland</aff><aff id="AF0004"><label>4</label>University of Melbourne</aff><pub-date pub-type="ppub"><month>4</month><year>2018</year></pub-date><pub-date iso-8601-date="2018-04-01" pub-type="epub"><day>01</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>4</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>44</volume><issue>Suppl 1</issue><issue-title>Abstracts for the Sixth Biennial SIRS Conference</issue-title><fpage>S66</fpage><lpage>S66</lpage><permissions><copyright-statement>&#x000a9; Maryland Psychiatric Research Center 2018.</copyright-statement><copyright-year>2018</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="sby014.169.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Clozapine has long been considered the gold standard antipsychotic for treatment refractory schizophrenia (TRS). There have been a number of recent meta-analyses of efficacy of clozapine on psychotic symptoms and effectiveness in reducing hospitalisations that have sparked debate on the role of clozapine.</p></sec><sec id="s2"><title>Methods</title><p>Current literature regarding the efficacy of clozapine for TRS, including pair-wise and network meta-analyses of RCTs with reported outcomes of total psychotic symptoms, positive symptoms and negative symptoms were reviewed. We also examined the results of a meta-analysis of the effectiveness of clozapine on reducing hospitalisations based in RCTs and observational studies.</p></sec><sec id="s3"><title>Results</title><p>Two recent meta-analyses: Samara et al (2016), a network meta-analysis in JAMA Psychiatry; and Siskind et al (2016) a pairwise meta-analysis in BJPsych, found similar equivocal results for total psychotic symptoms. However, Siskind et al (2016) found clozapine to be superior to other anti-psychotics for positive symptoms. Factors influencing the difference in results included pair-wise vs network methodology and sensitivity analyses of pharmaceutical industry support. Of note, only 40% of people with TRS responded to clozapine. Clozapine&#x02019;s effectiveness for reducing hospitalisations was significant, with a relative risk of 0.74 (95%CI 0.69&#x02013;0.80).</p></sec><sec id="s4"><title>Discussion</title><p>There are a lack of recent non-industry funded randomised control trials of clozapine compared to SGAs, which hinders an equivocal statement about the superiority of clozapine for total psychotic symptoms. However, there is evidence to suggest that clozapine is superior to other antipsychotics, including SGAs, for positive symptoms. In terms of effectiveness, initiation of clozapine can reduce the proportion of people hospitalised and reduce bed days. Use of clozapine needs to be balanced against its adverse drug reaction profile. There remains a need for more effective treatments for TRS, and biomarkers to identify TRS.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>